ReviewEndocrine2012
The use of combination therapy in the treatment of postmenopausal osteoporosis.
Review in Endocrine, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed, 3 syntheses or guidelines pooled it, 27 citations in OpenAlex.
- Combination therapy with parathyroid hormone analogs and antiresorptive agents for osteoporosis: a systematic review and meta-analysis of randomized controlled trials.Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA · 2019Pooled it
- Combination therapy of anabolic and nonbisphosphonates antiresorptive agents for the treatment of osteoporosis: A meta-analysis.Medicine · 2017Pooled it
- Single and combined use of human parathyroid hormone (PTH) (1-34) on areal bone mineral density (aBMD) in postmenopausal women with osteoporosis: evidence based on 9 RCTs.Medical science monitor : international medical journal of experimental and clinical research · 2014Pooled it
- Two years of Denosumab and teriparatide administration in postmenopausal women with osteoporosis (The DATA Extension Study): a randomized controlled trial.The Journal of clinical endocrinology and metabolism · 2014Trial
- Trial
- Teriparatide and denosumab, alone or combined, in women with postmenopausal osteoporosis: the DATA study randomised trial.Lancet (London, England) · 2013Trial
- Nandrolone Decanoate for Postmenopausal Osteoporosis: A Systematic Review and Meta-Analysis of Randomized Trials.Cureus · 2025Review
- Physicochemical and biological properties of encapsulatedSaudi pharmaceutical journal : SPJ : the official publication of the Saudi Pharmaceutical Society · 2024Article
- Osteoporosis: Current Concepts.Joints · 2018Review
- Use of combination therapy in the treatment of primary osteoporosis: protocol for a network meta-analysis of randomised trials.BMJ open · 2016Article
- Trajectories of Bone Remodeling Markers and Bone Mineral Density during Treatment with Strontium Ranelate in Postmenopausal Women Previously Treated with Bisphosphonates.Clinical medicine insights. Endocrinology and diabetes · 2014Article
- Is there a role for combination therapy for osteoporosis?Endocrine · 2013Article
- A mechanical model for predicting the probability of osteoporotic hip fractures based in DXA measurements and finite element simulation.Biomedical engineering online · 2012Article
- Skeletal and extraskeletal actions of denosumab.Endocrine · 2012Review
- New advances in imaging osteoporosis and its complications.Endocrine · 2012Review
- Article
- New understanding and treatments for osteoporosis.Endocrine · 2012Review
- Potential antiosteoporotic agents from plants: a comprehensive review.Evidence-based complementary and alternative medicine : eCAM · 2012Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
In recent years, there has been growing interest in the potential use of combination therapy in the management of osteoporosis in postmenopausal women. Possible regimens include sequential or combined use of anti-resorptive drugs or combinations of anabolic and anti-resorptive agents, given concurrently or in sequence. Combined therapy with anti-resorptive drugs usually produces greater increases in bone mineral density (BMD) than monotherapy but there is no evidence that this results in greater anti-fracture efficacy. The use of bisphosphonates before strontium ranelate or PTH peptides blunts the BMD response. Combined PTH and anti-resorptive therapy results in more rapid gains in spine BMD and a greater increase in hip BMD than PTH monotherapy in the first year of treatment but greater gains in both spine and hip BMD are seen with PTH monotherapy than combined therapy after 2 years of treatment. Anti-resorptive therapy after PTH therapy maintains or increases the gains in BMD. Further research is required to establish the cost-effectiveness and safety of combined and sequential regimens.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.